213 related articles for article (PubMed ID: 33168793)
1. Comprehensive analysis of
Zhou C; Li M; Guo Z; Li K; Zhai X; Xie Y; Yang X; Wu Y; Xiao W; Xu W
J Genet; 2020; 99():. PubMed ID: 33168793
[TBL] [Abstract][Full Text] [Related]
2. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
[TBL] [Abstract][Full Text] [Related]
3. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC.
Melchior L; Hirschmann A; Hofman P; Bontoux C; Concha A; Mrabet-Dahbi S; Vannuffel P; Watkin E; Putzová M; Scarpino S; Cayre A; Martin P; Stoehr R; Hartmann A
Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039
[TBL] [Abstract][Full Text] [Related]
4. Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.
Piton N; Ruminy P; Gravet C; Marchand V; Colasse É; Lamy A; Naoures Mear CL; Bibeau F; Marguet F; Guisier F; Salaün M; Thiberville L; Jardin F; Sabourin JC
Lab Invest; 2018 Mar; 98(3):371-379. PubMed ID: 29251734
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
[TBL] [Abstract][Full Text] [Related]
6. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
[TBL] [Abstract][Full Text] [Related]
7. Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.
Tang Z; Zhang J; Lu X; Wang W; Chen H; Robinson MK; Cheng J; Tang G; Medeiros LJ
Mod Pathol; 2018 Feb; 31(2):307-312. PubMed ID: 28914263
[TBL] [Abstract][Full Text] [Related]
8. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract][Full Text] [Related]
9. Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach.
Yoon HJ; Sohn I; Cho JH; Lee HY; Kim JH; Choi YL; Kim H; Lee G; Lee KS; Kim J
Medicine (Baltimore); 2015 Oct; 94(41):e1753. PubMed ID: 26469915
[TBL] [Abstract][Full Text] [Related]
10. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Tejpar S; Sartore-Bianchi A; Hechtman JF; Christiansen J; Novara L; Tebbutt N; Fucà G; Antoniotti C; Kim ST; Murphy D; Berenato R; Morano F; Sun J; Min B; Stephens PJ; Chen M; Lazzari L; Miller VA; Shoemaker R; Amatu A; Milione M; Ross JS; Siena S; Bardelli A; Ali SM; Falcone A; de Braud F; Cremolini C
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29370427
[TBL] [Abstract][Full Text] [Related]
11. Identification of
Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
[TBL] [Abstract][Full Text] [Related]
12. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
[TBL] [Abstract][Full Text] [Related]
15. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
Song Z; Yu X; Zhang Y
Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639
[TBL] [Abstract][Full Text] [Related]
17. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
18. Clinical Utility and Performance of an Ultrarapid Multiplex RNA-Based Assay for Detection of ALK, ROS1, RET, and NTRK1/2/3 Rearrangements and MET Exon 14 Skipping Alterations.
Chu YH; Barbee J; Yang SR; Chang JC; Liang P; Mullaney K; Chan R; Salazar P; Benayed R; Offin M; Drilon A; Ladanyi M; Nafa K; Arcila ME
J Mol Diagn; 2022 Jun; 24(6):642-654. PubMed ID: 35430374
[TBL] [Abstract][Full Text] [Related]
19. RET, ROS1 and ALK fusions in lung cancer.
Takeuchi K; Soda M; Togashi Y; Suzuki R; Sakata S; Hatano S; Asaka R; Hamanaka W; Ninomiya H; Uehara H; Lim Choi Y; Satoh Y; Okumura S; Nakagawa K; Mano H; Ishikawa Y
Nat Med; 2012 Feb; 18(3):378-81. PubMed ID: 22327623
[TBL] [Abstract][Full Text] [Related]
20.
Mulkidjan RS; Saitova ES; Preobrazhenskaya EV; Asadulaeva KA; Bubnov MG; Otradnova EA; Terina DM; Shulga SS; Martynenko DE; Semina MV; Belogubova EV; Tiurin VI; Amankwah PS; Martianov AS; Imyanitov EN
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
